That’s precisely the problem here Suzuki. OSL reckon they have more than satisfied the protocols etc. BSI have other ideas. Unlike the FDA which is much clearer as to what the requirements are ie Controlled study etc with 2 separate groups one with the Oncosil device and the other without. The Europeans appear to be more vague.
With the value of hindsight, Oncosil would have been better off going for FDA approval rather than EU approval.
Ann: CE Marking Update, page-11
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $137.7K | 11.46M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1719369 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3242606 | 5 |
View Market Depth
| Last trade - 15.10pm 18/10/2024 (20 minute delay) ? |
| OSL (ASX) Chart |